Clinical Trial Detail

NCT ID NCT04332367
Title Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

lung non-squamous non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel + Ramucirumab

Age Groups: senior adult

No variant requirements are available.